Companies are developing myostatin inhibitors for GLP-1RA- related muscle loss, but some experts doubt their necessity.

have recently been testing myostatin inhibitors in phase three trials in patients with spinal muscular atrophy, or SMA, a ...

The prospects of a new class of Duchenne muscular dystrophy therapies have taken another downturn after Roche abandoned development of RG6206, a myostatin inhibitor. The Swiss group revealed the ...